Acadian Asset Management
SYRE icon

Acadian Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Acadian Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
+2,296
New +$168K ﹤0.01% 1632
2024
Q4 		– Sell
-814
Closed -$23K – 2148
2024
Q3 		$23K Buy
+814
New +$22.7K ﹤0.01% 1961
2024
Q1 		– Sell
-1,169
Closed -$25K – 1780
2023
Q4 		$25K Sell
1,169
-10,719
-90% -$148K ﹤0.01% 1570
2023
Q3 		$145K Sell
11,888
-43,767
-79% -$579K ﹤0.01% 1247
2023
Q2 		$625K Hold
55,655
– – ﹤0.01% 996
2023
Q1 		$402K Hold
55,655
– – ﹤0.01% 1108
2022
Q4 		$625K Buy
55,655
+36,913
+197% +$663K ﹤0.01% 979
2022
Q3 		$245K Buy
18,742
+2,207
+13% +$27.3K ﹤0.01% 1164
2022
Q2 		$208K Buy
16,535
+10,559
+177% +$370K ﹤0.01% 1190
2022
Q1 		$342K Buy
5,976
+743
+14% +$62.4K ﹤0.01% 1088
2021
Q4 		$620K Buy
+5,233
New +$826K ﹤0.01% 954
2019
Q2 		– Sell
-343
Closed -$69K – 2030
2019
Q1 		$69K Buy
+343
New +$71.5K ﹤0.01% 1607
2018
Q4 		– Sell
-2,169
Closed -$519K – 1827
2018
Q3 		$519K Sell
2,169
-755
-26% -$176K ﹤0.01% 870
2018
Q2 		$773K Buy
2,924
+1,690
+137% +$416K ﹤0.01% 796
2018
Q1 		$307K Buy
1,234
+831
+206% +$150K ﹤0.01% 967
2017
Q4 		$54K Buy
403
+221
+121% +$27K ﹤0.01% 1214
2017
Q3 		$22K Buy
+182
New +$17.1K ﹤0.01% 1214
2017
Q1 		– Sell
-19
Closed -$2K – 1767
2016
Q4 		$2K Buy
+19
New +$2.77K ﹤0.01% 1572

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Acadian Asset Management's SYRE Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,296 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #1632 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in SYRE as recently as Q3 2024.

Acadian Asset Management first reported a position in SYRE in Q4 2016 and has held it in 18 quarters since. The position peaked at $773K in Q2 2018. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Acadian Asset Management held 2,296 shares of Spyre Therapeutics worth $203K as of Q2 2026.
  • Spyre Therapeutics was a new Acadian Asset Management position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1632 holding.
  • Acadian Asset Management first reported a position in Spyre Therapeutics in Q4 2016 and has held it in 18 quarters since.
  • Acadian Asset Management's Spyre Therapeutics position peaked at $773K in Q2 2018.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.